Medical Devices & Technology

Prague – September 08, 2026 -- BTL has formally established a dedicated laser division and confirmed the upcoming launch of EXOLASE ONE®, a system it describes as the first medical application of fused erbium laser technology, treating an entire face in under 10 minutes.

BTL creates sixth core division to house new laser technology

The laser unit becomes BTL's sixth main division, joining existing operations in aesthetics, mental wellness, rehabilitation, cardiology and robotics. The move marks a structural expansion for the medical and aesthetic technology group as it pushes into a new laser hardware category.

Prague – September 08, 2026 -- BTL has established a dedicated laser division and will launch its flagship EXOLASE ONE system, the first medical application of fused erbium laser technology, marking the company's sixth core business line.

EXOLASE ONE merges multiple erbium wavelengths into a single beam

The system combines several erbium laser wavelengths into one light beam, treating the same tissue location simultaneously. BTL states this creates a new form of laser-tissue interaction that overcomes prior limitations in clinical efficacy, treatment speed and patient comfort for facial rejuvenation lasers.

Clinical researcher reports full-face treatment in under 10 minutes

Dr. Reha Yavuzer, one of the first clinical researchers on the platform, said the technology covers treatment areas that typically require multiple ablative and non-ablative systems, condensing the procedure into a full-face treatment completed in under 10 minutes.

Austin, Texas – September 08, 2026 -- The Texas Cardiac Arrhythmia Institute (TCAI) at St. David's Medical Center has become the first center in the United States to enroll a patient in a clinical trial evaluating a next-generation pulsed field ablation mapping and ablation system for paroxysmal and persistent atrial fibrillation.

TCAI performs first US procedure under global trial protocol

Andrea Natale, M.D., executive medical director of TCAI and global principal investigator for the trial, performed the inaugural procedure. The study is designed to assess the safety and efficacy of the catheter-based system in patients with paroxysmal atrial fibrillation, defined as symptomatic episodes lasting seven days or less, and persistent atrial fibrillation, sustained arrhythmia lasting longer than one week.

Hong Kong – September 08, 2026 -- Medtronic (NYSE: MDT) will invest approximately $700 million in Hong Kong-based Cornerstone Robotics as part of a strategic alliance granting the U.S. medtech giant distribution rights to the Sentire surgical robotic system in select markets outside the United States where the device is approved.

Medtronic gains distribution rights to Sentire outside the U.S.

The agreement covers markets where Sentire has already secured regulatory clearance, positioning the system alongside Medtronic's existing Hugo robotic surgical platform. Sentire received approval from China's National Medical Products Administration in 2024, followed by CE marking in the European Union and clearance from Singapore's Health Sciences Authority in May 2026 for general, gynecological, thoracic and urological minimally invasive procedures.

Hong Kong – September 08, 2026 -- Medtronic (NYSE: MDT) will make a strategic investment of approximately $700 million in Hong Kong-based Cornerstone Robotics, securing distribution rights for the Sentire surgical system in select markets outside the United States where the device is already cleared.

Medtronic secures rights to Sentire outside the US market

The agreement gives Medtronic distribution rights to Cornerstone Robotics' Sentire surgical system in ex-US markets where regulatory approval has already been granted. Matt Anderson, Senior Vice President and President of Medtronic's surgical solutions division, said the deal expands robotics choice for patients and positions Sentire as a complement to Medtronic's existing Hugo platform.

SHERIDAN, WYOMING -- July 22, 2026 -- Royal Philips has received FDA 510(k) clearance for its next-generation reusable SpO₂ clip sensor, a pulse oximetry device built around internal optical refinements that improve signal quality. In desaturation testing, the sensor posted an accuracy result nearly twice as tight as the level recommended by ISO and recognized by the FDA. It also held accuracy within half a percentage point between light and dark skin pigmentation groups tested. The clearance extends Philips' broader pulse oximetry portfolio and follows a validation program built specifically around performance across diverse patient populations.

SHERIDAN, WYOMING -- July 22, 2026 -- Royal Philips has launched Alturion, a new ultrasound system built for departments that run high patient volumes across varied exam types. The system pairs AI-powered workflow tools with imaging hardware designed to hold up across shift changes and multiple users. Alturion has received FDA 510(k) clearance and CE mark certification, making it available now in the U.S. and Europe. Philips positions the launch as an expansion of its ultrasound portfolio rather than a standalone product, built to share transducers and interface design with existing systems already in clinical use.

SHERIDAN, WYOMING -- June 09, 2026 -- Philips has put its VeriSight Pro 3D intracardiac echocardiography (ICE) technology in front of a wider audience through a feature on the BBC's technology program Tech Now, filmed during a live structural heart procedure in Copenhagen. The technology places a miniature ultrasound probe on the tip of a catheter, threading it through a vein into the heart to deliver real-time three-dimensional images of anatomy, valves, and treatment devices. For interventional teams, it offers an alternative to passing a larger probe down the patient's esophagus under general anaesthesia. The result is a more precise and less invasive route to treating structural heart disease.

SHERIDAN, WYOMING - April 14, 2026 - Corvex and Movano Health have announced the closing of their all-stock merger, completing a structural consolidation for the Pleasanton, California-based developer of women's health wearables. The transaction follows a sequence of concurrent corporate developments at Movano, including a Nasdaq deficiency notification tied to a delayed quarterly filing and a board-initiated process to evaluate options for maximizing shareholder value. Movano's portfolio centers on the Evie Ring, a smart ring designed specifically for women's health monitoring, and a patented radio frequency platform targeting non-invasive blood pressure and glucose measurement. Together, these developments mark a period of significant transition for the company across its corporate, regulatory, and product dimensions.

SHERIDAN, WYOMING - April 14, 2026 - Nanodropper has developed the only FDA-listed, volume-reducing adaptor for commercial eyedrop bottles, targeting a structural inefficiency in ophthalmic drug delivery that decades of clinical research have identified but pharmaceutical packaging has not resolved. The device attaches by twisting onto a compatible bottle and reduces dispensed drop volume by more than 60%. Standard eyedrop bottles produce drops approximately five times larger than the eye can absorb, causing up to 80% of each dose to be lost through facial overflow or tear duct drainage into systemic circulation. Clinical evidence indicates smaller drops deliver equivalent therapeutic effect while reducing systemic absorption and associated side effects.